2.1
Efanesoctocog alfa (Altuvoct, Swedish Orphan Biovitrum) is indicated for 'treatment and prophylaxis of bleeding in patients 2 years and above with severe or moderate haemophilia A (≤ 5% endogenous plasma factor VIII activity).'
2 Information about efanesoctocog alfa
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for efanesoctocog alfa.
Price
2.3
The list price per vial of 1,000 IU efanesoctocog alfa is £2,400 (£2.40 per IU; company submission). It is available as 250 IU, 500 IU, 750 IU, 1,000 IU, 2,000 IU, 3,000 IU and 4,000 IU vials.
2.4
The company has a commercial arrangement. This makes efanesoctocog alfa available to the NHS with a discount. The size of the discount is commercial in confidence.